Fast Five Quiz: Breast Cancer Treatment

Pavani Chalasani, MD, MPH


July 12, 2021

The BRCA1 mutation is an actionable mutation for the treatment of breast cancer, as PARP inhibitors are approved for patients with metastatic breast cancer who harbor germline mutations in BRCA1 and BRCA2. Other biomarkers associated with targeted therapies for breast cancer include:

  • PIK3CA activating mutation

  • PD-L1 expression

  • NTRK fusion

  • MSI-H/dMMR

BRAF, C-KIT, and KRAS2 are mutations associated with targeted therapies in malignancies other than breast cancer.

For additional information, refer to the guidelines from the National Comprehensive Cancer Network (NCCN), the guidelines from the American Society of Clinical Oncology (ASCO), and the guidelines from the European Society for Medical Oncology (ESMO).

Learn more about targeted therapies for breast cancer.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.